NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the July 2013 NCCN Trends™ Survey, which focused on Metastatic Castrate Resistant Prostate Cancer. This survey was sent to U.S. and International users of NCCN.org.

DEMOGRAPHICS

Distribution of Respondent Types (n = 1,083)

- Physician/Surgeon/Oncologist: 76%
- Nurse/Oncology Nurse or Clinical Nurse Specialist: 10%
- Pharmacist: 4%
- Physician Assistant or Nurse Practitioner: 4%
- Other Clinician: 5%

Note: Percentages may not total 100 because of rounding.
Q1. Do you treat patients with metastatic castrate resistant prostate cancer (mCRPC)? (n = 1,083)

- Yes: 74%
- No: 26%
Q2. Please select from the following agents, both approved and in development, of which you are currently familiar for the treatment of mCRPC. Please select all that apply. (n = 707)

- Radium Ra 223 dichloride: 41%
- Enzalutamide: 48%
- Abiraterone acetate: 79%
- Ipilimumab: 26%
- TAK-700 / orteronel: 13%
- ABR-215050 / tasquinimod: 6%
- XL-184 / cabozantinib: 20%
- Denosumab: 62%
- ARN-509: 6%
- Other: 21%
Q3. Based on information currently available, how likely are you to utilize the following agents if granted FDA approval?

11% Extremely Disinterested
11% Disinterested
20% Neutral
12% Interested
49% Extremely Interested

Results: July 2013
PROSTATE CANCER

TAK-700 / orteronel (n = 568)
11% 11% 49% 23% 6%

ABR-215050 / tasquinimod (n = 552)
11% 13% 54% 19% 3%

XL-184 / cabozantinib (n = 575)
11% 10% 39% 31% 10%

ARN-509 (n = 553)
12% 12% 54% 19% 4%
Q4. Focusing solely on the patients you have seen in the past month with symptomatic mCRPC, what percent would you estimate have the following metastatic disease sites?

Results: July 2013

PROSTATE CANCER

<table>
<thead>
<tr>
<th>Metastatic Disease Sites</th>
<th>Percentage of Respondents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone metastases only</td>
<td></td>
</tr>
<tr>
<td>(n = 595)</td>
<td>3% 5% 9% 13% 18% 53%</td>
</tr>
<tr>
<td>Visceral metastases only</td>
<td></td>
</tr>
<tr>
<td>(n = 545)</td>
<td>54% 27% 11% 6% 1%</td>
</tr>
<tr>
<td>Both bone and visceral</td>
<td></td>
</tr>
<tr>
<td>metastases (n = 569)</td>
<td>19% 24% 27% 15% 9% 7%</td>
</tr>
</tbody>
</table>

Percentage of Respondents
Q5. Of the patients you have seen in the past month with symptomatic mCRPC and bone metastases only, what percent would you estimate are currently being treated with each of the following treatment options?

- cabazitaxel (n = 426)
- sipuleucel-T (n = 362)
- docetaxel (n = 524)
- radium Ra 223 dichloride (n = 370)
- enzalutamide (n = 380)
- abiraterone acetate (n = 489)
- other chemotherapy agent (n = 372)
- other product(s) (n = 353)
- no treatment (n = 353)

Results: July 2013

PROSTATE CANCER
**NCCN Trends™** is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an NCCN Trends™ survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

**Christine MacCracken, MSHEd, BSN**  
Senior Director, Business Insights  
215.690.0557  
maccracken@nccn.org

**National Comprehensive Cancer Network® (NCCN®)**

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 23 of the world’s leading cancer centers, is dedicated to improving the quality, effectiveness, and efficiency of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

**NCCN.org** - For Clinicians • **NCCN.org/patients** - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.*